Dr Robert Evans describes how the continuous cycle of interstitial cystitis (IC) may begin—and evolve—and how multimodal therapy can help. ELMIRON® is indicated for the relief of bladder pain or discomfort that is associated with IC.
Continuous Cycle of IC
Robert J. Evans, MD
Associate Professor of Urology
Wake Forest University
Janssen Pharmaceuticals, Inc. Consultant Speaker
*Bacterial cystitis, pelvic surgery, childbirth, urologic instrumentation.
Adapted with permission from Evans RJ. Rev Urol. 2002;4(suppl 1):S16-S20.
Copyright© MedReviews©, LLC. Adapted with permission of MedReviews®, LLC. Evans RJ. Treatment approaches for interstitial cystitis: multimodality therapy. Rev Urol. 2002;4(suppl 1):S16-S20. Reviews in Urology is a copyrighted publication of MedReviews©, LLC. All rights reserved.
Important Safety Information
- Contraindications: ELMIRON® is contraindicated in patients with known hypersensitivity to the drug, structurally related compounds, or excipients
- Anticoagulant Activity: ELMIRON® is a weak anticoagulant (blood thinner) which may increase bleeding. Patients undergoing invasive surgery or having signs/symptoms of underlying coagulopathy or other increased risk of bleeding (due to anticoagulant therapy or high doses of anti-inflammatory drugs) should be evaluated for the risk of hemorrhage
- Alopecia: In clinical trials of ELMIRON®, alopecia began within the first 4 weeks of treatment. Ninety-seven percent (97%) of the cases of alopecia reported were alopecia areata, limited to a single area on the scalp
- Use in Pregnancy: ELMIRON® is a Pregnancy Category B drug
- Most Common Adverse Reactions (frequency 1% to 4%): Alopecia (4%), diarrhea (4%), nausea (4%), headache (3%), rash (3%), dyspepsia (2%), abdominal pain (2%), liver function abnormalities (1%), dizziness (1%)